QUMAS, the leading provider of Compliance Solutions to highly regulated industries, today announced the launch QUMAS ComplianceSP on Microsoft SharePoint 2010. QUMAS ComplianceSP is an innovative document and quality management solution, combining the power of SharePoint 2010 with the regulatory domain expertise that QUMAS has proven over 17 years of providing core compliance solutions to regulated industries.
QUMAS, the leading provider of Compliance Solutions to highly regulated companies, has announced the achievement of the Gold Content Management competency in the Microsoft Partner Network, demonstrating its ability to meet evolving customer needs in today’s dynamic business environment. To earn a Microsoft Gold competency, organizations must complete a rigorous set of tests to prove their level of technology expertise, have the right number of Microsoft Certified Professionals, submit customer references and demonstrate their commitment to customer satisfaction.
iThemba Pharmaceuticals and Chemonaut announce a collaboration on providing a screening compound re-synthesis service. The collaboration has stemmed from both companies recognising that in the dynamically changing world of screening compound supply, it has become more difficult to resource hit compounds from their original source.
Randox has been supplying the world’s leading CRO’s, Pharmaceutical and Biotech companies for nearly three decades, and has unrivalled in-house technical know-how, whether in the development of new biomarker assays, companion diagnostics or the manufacture of the highest quality clinical diagnostic reagents.
METTLER TOLEDO Garvens announces the launched of its newest ground-breaking and innovative pharmaceutical serialisation solution which is already being praised by leading pharmaceutical companies as one of the best systems available in the fight against product counterfeiting.
METTLER TOLEDO Garvens announces the launch of its newest pharmaceutical serialisation and weighing combination solution the XS2 MV (Mark and Vision) system. This new system was developed in close co-operation with world leading pharmaceutical companies to offer a solution with such a high degree of operational flexibility that it offers over 375 standard configurations.
Medpace, Inc. continues their European expansion with the acquisition of Medical Consulting Dr. Schlichtiger GmbH, a European CRO with key expertise in drug development and special focus on regulatory consulting and drug safety.
Medpace, Inc. today announced the addition of Samer E. Kaba, MD, as a Medical Director with therapeutic expertise in guiding global clinical trials in the area of Neuroscience. Dr. Kaba brings a wealth of clinical development expertise in the areas of neurology, psychiatry, and analgesia. As a Medpace Medical Director, Dr. Kaba will be engaged with Medpace clients in formulating clinical development plans and strategy, designing clinical trials, and providing medical oversight for clinical trials in his areas of expertise. Dr. Kaba joins an experienced neurology operations team specifically in Parkinson’s, Alzheimer’s, multiple sclerosis, and pain.
Medpace Reference Laboratories (MRL) central labs in China and India achieve CAP Accreditation, NGSP Level 1 and CDC Lipid Standardization Part III standardization, completing the company’s ability to deliver global, identical, highly standardized laboratory services in its own facilities.
Medpace, Inc. a global, full-service clinical research organization (CRO) announced that it has completed integration activities with Symbios Clinical, a CRO dedicated to medical device clinical trials which Medpace acquired earlier this year. Symbios Clinical will now be known as Medpace Medical Device (MMD) and will continue to provide expertise in pre-market, post-approval and postmarket / outcomes trials.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.